降保適錠 75 微公克 (法國廠)

国家: 台湾

语言: 中文

来源: 衛生福利部食品藥物管理署 (Ministry of Health and Welfare, Food And Drug Administration)

有效成分:

CLONIDINE HCL (CLONIDINE HYDROCHLORIDE)

可用日期:

裕利股份有限公司 台北市松山區南京東路四段126號10樓，10樓之1-3 (22853066)

ATC代码:

C02AC01

药物剂型:

錠劑

组成:

CLONIDINE HCL (CLONIDINE HYDROCHLORIDE) (2408000510) MG

每包单位数:

鋁箔盒裝

类:

製　劑

处方类型:

須由醫師處方使用

厂商:

DELPHARM REIMS 10 RUE COLONEL CHARBONNEAUX, 51100 REIMS, FRANCE FR

治疗领域:

clonidine

疗效迹象:

高血壓。

產品總結:

有效日期: 2026/03/29; 英文品名: CATAPRES TABLETS 75 μg

授权日期:

2011-03-29

资料单张

Druckfarben
Datum/Signatur
KORREKTUR ERBETEN
DRUCKFREIGABE
Auftrags-Nr.
21/0
erstellt
10.03.21
WO
Produktbezeichnung
CATAPRESAN
TABLETTEN 75 UG
TW
Maße in mm
160 X 420
PACKAGE INFORM.
PRXX
Artikel-Nr.
302148GI-01
CODE 244
Druckfarben
PANTONE BLACK C
kleinste Schriftgröße
7 PT
VORDERSEITE
302148GI-01
xxx
1
COMPOSITION:
1 tablet contains 2,6-dichloro-N-2-imidazolidinylidene
benzenamine hydrochloride
(=clonidine hydrochloride)
0.075mg
_EXCIPIENTS_
lactose monohydrate, calcium hydrogen phosphate anhydrous,
maize starch dried, silica colloidal anhydrous, povidone,
modified starch (corn starch, oxidized), stearic acid
CLINICAL PHARMACOLOGY
The anti-hypertension effect of clonidine HCl is generally
recognized as to stimulate alpha2-adrenoreceptors in the brain
stem. This action results in reduced sympathetic outflow from the
central nervous system and in decrease in peripheral resistance,
renal vascular resistance, heart rate, and blood pressure. Renal
blood flow and glomerular filtration rate remain essentially
unchanged.
INDICATIONS
Hypertension
DOSAGE AND ADMINISTRATION
Use under physician’s prescription.
Clonidine HCl may be employed alone or concomitantly with
other antihypertensive agents.
For the treatment of hypertensive crises, slow parenteral
administration is especially suitable due to the rapid onset of
action. Treatment of hypertension requires regular medical
supervision. The dose of clonidine HCl must be adjusted
according to the patient’s individual blood pressure response.
A daily dose in mild to moderate forms of hypertension,
0.075 mg to 0.150 mg twice daily are sufficient in most cases.
After a period of 2 – 4 weeks the dose may be increased if
necessary until the desired response is achieved.
Usually doses above 0.6 mg per day do not result in a further
marked drop in blood pressure. In severe hypertension it might
be necessary to increase the single dose further to 0.3 mg; this
could be repeated up to three times daily (0.9 mg).
_RENAL INSUFFICIENCY_
Dosage must be adjusted
•
according t